0
Skip to Content
Context Therapeutics
Who We Are
Our Technology
Pipeline
CTIM-76
CT-202
Patients
Careers
Investors & News
Context Therapeutics
Who We Are
Our Technology
Pipeline
CTIM-76
CT-202
Patients
Careers
Investors & News
Who We Are
Folder: Our Science
Back
Our Technology
Pipeline
CTIM-76
CT-202
Patients
Careers
Investors & News

Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6

Publications
Nov 9
Written by Martin Lehr
CLDN6
Martin Lehr
Previous
Previous

Determination of first in human dose of the T cell-redirecting bispecific antibody CT-95 targeting mesothelin and CD3

Next
Next

CTIM-76, a Highly Specific Claudin 6 Antibody

About Us
Leadership
Partnering
Contact Us

Our Technology
Pipeline
CTIM-76
CT-202

Patients
Clinical Trials
Expanded Access Policy
Investigator Led Trials

Investors & Media
News
Publications

Careers
Open Positions

Privacy Policy          Terms of Use

© Context Therapeutics Inc. 2026  |  All Rights Reserved